Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

20.70USD
19 Jan 2018
Change (% chg)

$-0.01 (-0.05%)
Prev Close
$20.71
Open
$20.78
Day's High
$21.25
Day's Low
$20.15
Volume
4,180,303
Avg. Vol
4,824,854
52-wk High
$37.94
52-wk Low
$10.85

Select another date:

Mon, Jan 15 2018

BRIEF-Teva Announces FDA Approval Of Trisenox To Treat Acute Promyelocytic Leukemia

* TEVA ANNOUNCES U.S. FDA APPROVAL OF TRISENOX® (ARSENIC TRIOXIDE) INJECTION FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA

BRIEF-Allergan PLC Reports 6.8 Pct Stake In Teva Pharmaceutical Industries As Of January 10, 2018

* ALLERGAN PLC REPORTS 6.8 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF JANUARY 10, 2018 - SEC FILING‍​

Boehringer, Teva settle Aggrenox pay-for-delay case for $54 million

Boehringer Ingelheim and Teva Pharmaceutical Industries Ltd have agreed to pay $54 million to resolve a class action accusing them of conspiring to keep a generic version of Boehringer's stroke prevention drug Aggrenox off the market.

Teva Pharm directors cut their salaries in half: board member

JERUSALEM The board of directors at Teva Pharmaceutical Industries , which is reducing its workforce by more than a quarter as part of a global overhaul, has taken a 50 percent pay cut, a board member said on Wednesday.

Teva Pharm directors cut their salaries in half -board member

JERUSALEM, Jan 10 The board of directors at Teva Pharmaceutical Industries , which is reducing its workforce by more than a quarter as part of a global overhaul, has taken a 50 percent pay cut, a board member said on Wednesday.

Teva Pharm agrees with workers on closing Jerusalem inhaler plant

TEL AVIV, Jan 10 Israel's Teva Pharmaceutical Industries said on Wednesday it had reached an agreement with workers on closing its inhaler factory in Jerusalem by the end of 2019, ending weeks of labour unrest at the facility.

Allergan forecasts 2018 revenue below estimates

Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

UPDATE 1-Allergan forecasts 2018 revenue below estimates

Jan 8 Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

Allergan forecasts 2018 revenue below estimates

Jan 8 Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva

* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY

Select another date: